Aboyans V, Ricco JB, Bartelink ML, Björck M, Brodmann M, Cohner T, et al. ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Kardiol Pol (Polish Heart. Journal). 2017;75:1065–160. https://doi.org/10.5603/KP.2017.0216.

Article  Google Scholar 

Iida O, Takahara M, Soga Y, Hirano K, Yamauchi Y, Zen K, et al. The characteristics of in-stent restenosis after drug-eluting stent implantation in femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy for these lesions. JACC Cardiovasc Interv. 2016;9:828–34. https://doi.org/10.1016/j.jcin.2016.01.007.

Article  PubMed  Google Scholar 

Iida O, Takahara M, Soga Y, Yamaoka T, Fujihara M, Kawasaki D, et al. 1-year outcomes of fluoropolymer-based drug-eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration. JACC Cardiovasc Interv. 2022;15:630–8. https://doi.org/10.1016/j.jcin.2022.01.019.

Article  PubMed  Google Scholar 

Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16–23. https://doi.org/10.1016/j.jacc.2011.09.036.

Article  PubMed  Google Scholar 

Ichihashi S, Takahara M, Iida O, Suzuki K, Yamaoka T, Maeda K, et al. Clinical impact of stent graft thrombosis in femoropopliteal arterial lesions. JACC Cardiovasc Interv. 2021;14:1137–47. https://doi.org/10.1016/j.jcin.2021.03.030.

Article  PubMed  Google Scholar 

Suzuki K, Takahara M, Tobita K, Hayakawa N, Mori S, Iwata Y, et al. Contemporary therapy of femoropopliteal in-stent restenosis / occlusion, 36-month follow up study. Vasc Endovasc Surg. 2024;58:693–700. https://doi.org/10.1177/15385744241253170.

Article  Google Scholar 

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40:2632–53. https://doi.org/10.1093/eurheartj/ehz372.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, et al. Total ischemic event reduction with Rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial. J Am Coll Cardiol. 2021;78:317–26. https://doi.org/10.1016/j.jacc.2021.05.003.

Article  CAS  PubMed  Google Scholar 

Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212–20. https://doi.org/10.1002/ccd.25387.

Article  PubMed  PubMed Central  Google Scholar 

Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20:1141–50. https://doi.org/10.1016/j.jvir.2009.05.031.

Article  PubMed  Google Scholar 

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–47. https://doi.org/10.1161/CIRCULATIONAHA.110.009449.

Article  PubMed  Google Scholar 

Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x.

Article  CAS  PubMed  Google Scholar 

Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009;50:1462–e731. https://doi.org/10.1016/j.jvs.2009.09.044.

Article  PubMed  Google Scholar 

Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994–2004. https://doi.org/10.1056/NEJMoa2000052.

Article  CAS  PubMed  Google Scholar 

Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021;42:4013–24. https://doi.org/10.1093/eurheartj/ehab390.

Article  CAS  PubMed  Google Scholar 

Bhuta S, Ariss RW, Ding L, Nazir S, Magee GA, Garg PK, et al. Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention. J Vasc Surg. 2023;78:498–e5051. https://doi.org/10.1016/j.jvs.2023.04.026.

Article  PubMed  PubMed Central  Google Scholar 

Dohi T, Iida O, Soga Y, Hirano K, Suzuki K, Takahara M, et al. Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions. J Vasc Surg. 2014;59:1009–e10151. https://doi.org/10.1016/j.jvs.2013.10.050.

Article  PubMed  Google Scholar 

Ishihara T, Iida O, Okamoto S, Fujita M, Masuda M, Nanto K, et al. Potential mechanisms of in-stent occlusion in the femoropopliteal artery: an angioscopic assessment. Cardiovasc Interv Ther. 2017;32:313–7. https://doi.org/10.1007/s12928-016-0411-3.

Article  PubMed  Google Scholar 

Mori H, Lutter C, Yahagi K, Harari E, Kutys R, Fowler DR, et al. Pathology of chronic total occlusion in bare-metal versus drug-eluting stents: implications for revascularization. JACC Cardiovasc Interv. 2017;10:367–78. https://doi.org/10.1016/j.jcin.2016.11.005.

Article  PubMed  Google Scholar 

Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB. Impact of runoff on superficial femoral artery endoluminal interventions for rest pain and tissue loss. J Vasc Surg. 2008;48:619–25. https://doi.org/10.1016/j.jvs.2008.04.013. discussion 625.

Article  PubMed  Google Scholar 

Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021;42:4624–34. https://doi.org/10.1093/eurheartj/ehab702.

Article  CAS  PubMed  Google Scholar 

Smits PC, Frigoli E, Tijssen J, Jüni P, Vranckx P, Ozaki Y, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial. Circulation. 2021;144:1196–211. https://doi.org/10.1161/CIRCULATIONAHA.121.056680.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciou WS, Wang CC, Lin FJ, Chao TF, Lin SY. Comparison of different direct oral anticoagulant regimens in atrial fibrillation patients with high bleeding risk. Heart Rhythm. 2024;21:715–22. https://doi.org/10.1016/j.hrthm.2024.01.025.

Article  PubMed  Google Scholar